Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000017.xml
Exp Clin Endocrinol Diabetes 2024; 132(11): 631-641
DOI: 10.1055/a-2399-1174
DOI: 10.1055/a-2399-1174
Article
Dihydromyricetin Improves High Glucose-Induced Dopaminergic Neuronal Damage by Activating AMPK-Autophagy Signaling Pathway
Supported by: Hengyang Science and Technology Board 202330046219Supported by: Health Commission of Hunan Province C202303076198
Supported by: Natural Science Foundation of Hunan Province 2021JJ30595,2022JJ50161
Abstract
Introduction In recent years, a growing number of clinical and biological studies have shown that patients with type 2 diabetes mellitus (T2DM) are at increased risk of developing Parkinson’s disease (PD). Prolonged exposure to hyperglycemia results in abnormal glucose metabolism, which in turn causes pathological changes similar to PD, leading to selective loss of dopaminergic neurons in the compact part of the substantia nigra. Dihydromyricetin (DHM) is a naturally occurring flavonoid with various biological activities including antioxidant and hepatoprotective properties. In this study, the effect of DHM on high glucose-induced dopaminergic neuronal damage was investigated.
Methods The potential modulatory effects of DHM on high glucose-induced dopaminergic neuronal damage and its mechanism were studied.
Results DHM ameliorated high glucose-induced dopaminergic neuronal damage and autophagy injury. Inhibition of autophagy by 3-methyladenine abrogated the beneficial effects of DHM on high glucose-induced dopaminergic neuronal damage. In addition, DHM increased levels of p-AMP-activated protein kinase (AMPK) and phosphorylated UNC51-like kinase 1. The AMPK inhibitor compound C eliminated DHM-induced autophagy and subsequently inhibited the ameliorative effects of DHM on high glucose-induced dopaminergic neuronal damage.
Discussion DHM ameliorates high glucose-induced dopaminergic neuronal damage by activating the AMPK-autophagy pathway.
Publication History
Received: 23 April 2024
Accepted after revision: 21 August 2024
Accepted Manuscript online:
21 August 2024
Article published online:
26 September 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Ali MK, Pearson-Stuttard J, Selvin E. et al. Interpreting global trends in type 2 diabetes complications and mortality. Diabetologia 2022; 65: 3-13 DOI: 10.1007/s00125-021-05585-2.
- 2 Tofaris GK. Initiation and progression of alpha-synuclein pathology in Parkinson’s disease. Cell Mol Life Sci 2022; 79: 210 DOI: 10.1007/s00018-022-04240-2.
- 3 Vidovic M, Rikalovic MG. Alpha-synuclein aggregation pathway in Parkinson’s disease: Current status and novel therapeutic approaches. Cells 2022; 11 DOI: 10.3390/cells11111732.
- 4 Pezzoli G, Cereda E, Amami P. et al. Onset and mortality of Parkinson’s disease in relation to type II diabetes. J Neurol 2023; 270: 1564-1572 DOI: 10.1007/s00415-022-11496-y.
- 5 Komici K, Femminella GD, Bencivenga L. et al. Diabetes mellitus and Parkinson’s disease: A systematic review and meta-analyses. J Parkinsons Dis 2021; 11: 1585-1596 DOI: 10.3233/JPD-212725.
- 6 Tan C, Liu X, Zhang X. et al. Fyn kinase regulates dopaminergic neuronal apoptosis in animal and cell models of high glucose (HG) treatment. BMC Mol Cell Biol 2021; 22: 58 DOI: 10.1186/s12860-021-00398-y.
- 7 Lim C, Zhen AX, Ok S. et al. Hesperidin protects SH-SY5Y neuronal cells against high glucose-induced apoptosis via regulation of MAPK signaling. Antioxidants (Basel) 2022; 11 DOI: 10.3390/antiox11091707.
- 8 Renaud J, Bassareo V, Beaulieu J. et al. Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: Preferential degeneration of the nigrostriatal motor pathway. Neurobiol Aging 2018; 69: 117-128 DOI: 10.1016/j.neurobiolaging.2018.05.010.
- 9 Li Y, Zhang Y, Wang L. et al. Autophagy impairment mediated by S-nitrosation of ATG4B leads to neurotoxicity in response to hyperglycemia. Autophagy 2017; 13: 1145-1160 DOI: 10.1080/15548627.2017.1320467.
- 10 Yang B, Yang Z, Hao L. Dynamics of a model for the degradation mechanism of aggregated alpha-synuclein in Parkinson’s disease. Front Comput Neurosci 2023; 17: 1068150 DOI: 10.3389/fncom.2023.1068150.
- 11 de Guzman ACV, Kang S, Kim EJ. et al. High-glucose diet attenuates the dopaminergic neuronal function in C. elegans, leading to the acceleration of the aging process. ACS Omega 2022; 7: 32339-32348 DOI: 10.1021/acsomega.2c03384.
- 12 Su CJ, Feng Y, Liu TT. et al. Thioredoxin-interacting protein induced alpha-synuclein accumulation via inhibition of autophagic flux: Implications for Parkinson’s disease. CNS Neurosci Ther 2017; 23: 717-723 DOI: 10.1111/cns.12721.
- 13 Sivakumar P, Nagashanmugam KB, Priyatharshni S. et al. Review on the interactions between dopamine metabolites and alpha-Synuclein in causing Parkinson’s disease. Neurochem Int 2023; 162: 105461 DOI: 10.1016/j.neuint.2022.105461.
- 14 Park JM, Lee DH, Kim DH. Redefining the role of AMPK in autophagy and the energy stress response. Nat Commun 2023; 14: 2994 DOI: 10.1038/s41467-023-38401-z.
- 15 Chung MM, Chen YL, Pei D. et al. The neuroprotective role of metformin in advanced glycation end product treated human neural stem cells is AMPK-dependent. Biochim Biophys Acta 2015; 1852: 720-731 DOI: 10.1016/j.bbadis.2015.01.006.
- 16 Yan Q, Han C, Wang G. et al. Activation of AMPK/mTORC1-mediated autophagy by metformin reverses Clk1 deficiency-sensitized dopaminergic neuronal death. Mol Pharmacol 2017; 92: 640-652 DOI: 10.1124/mol.117.109512.
- 17 Peng Y, Liu J, Shi L. et al. Mitochondrial dysfunction precedes depression of AMPK/AKT signaling in insulin resistance induced by high glucose in primary cortical neurons. J Neurochem 2016; 137: 701-713 DOI: 10.1111/jnc.13563.
- 18 Su J, Zhang J, Bao R. et al. Mitochondrial dysfunction and apoptosis are attenuated through activation of AMPK/GSK-3beta/PP2A pathway in Parkinson’s disease. Eur J Pharmacol 2021; 907: 174202 DOI: 10.1016/j.ejphar.2021.174202.
- 19 Wang W, Lv R, Zhang J. et al. circSAMD4A participates in the apoptosis and autophagy of dopaminergic neurons via the miR‑29c‑3p‑mediated AMPK/mTOR pathway in Parkinson’s disease. Mol Med Rep 2021; 24 DOI: 10.3892/mmr.2021.12179.
- 20 Guo Y, Jiang H, Wang M. et al. Metformin alleviates cerebral ischemia/reperfusion injury aggravated by hyperglycemia via regulating AMPK/ULK1/PINK1/Parkin pathway-mediated mitophagy and apoptosis. Chem Biol Interact 2023; 384: 110723 DOI: 10.1016/j.cbi.2023.110723.
- 21 Chen M, Peng L, Gong P. et al. Baicalein induces mitochondrial autophagy to prevent Parkinson’s disease in rats via miR-30b and the SIRT1/AMPK/mTOR pathway. Front Neurol 2021; 12: 646817 DOI: 10.3389/fneur.2021.646817.
- 22 Yerra VG, Areti A, Kumar A. Adenosine monophosphate-activated protein kinase abates hyperglycaemia-induced neuronal injury in experimental models of diabetic neuropathy: Effects on mitochondrial biogenesis, autophagy and neuroinflammation. Mol Neurobiol 2017; 54: 2301-2312 DOI: 10.1007/s12035-016-9824-3.
- 23 Chen P, Chen X, Zhang H. et al. Dexmedetomidine regulates autophagy via the AMPK/mTOR pathway to improve SH-SY5Y-APP cell damage induced by high glucose. Neuromolecular Med 2023; 25: 415-425 DOI: 10.1007/s12017-023-08745-2.
- 24 Zhang R, Zhang H, Shi H. et al. Strategic developments in the drug delivery of natural product dihydromyricetin: Applications, prospects, and challenges. Drug Deliv 2022; 29: 3052-3070 DOI: 10.1080/10717544.2022.2125601.
- 25 Hassanzadeh K, Rahimmi A, Moloudi MR. et al. Effect of lobeglitazone on motor function in rat model of Parkinson’s disease with diabetes co-morbidity. Brain Res Bull 2021; 173: 184-192 DOI: 10.1016/j.brainresbull.2021.05.011.
- 26 Wang Z, Feng S, Li Q. et al. Dihydromyricetin alleviates hippocampal ferroptosis in type 2 diabetic cognitive impairment rats via inhibiting the JNK-inflammatory factor pathway. Neurosci Lett 2023; 812: 137404 DOI: 10.1016/j.neulet.2023.137404.
- 27 Li Q, Chen N, Luo JD. et al. Dihydromyricetin improves Parkinson’s disease-like lesions in T2DM rats by activating AMPK/ULK1 pathway. Sheng Li Xue Bao 2023; 75: 59-68
- 28 Hou L, Jiang F, Huang B. et al. Dihydromyricetin ameliorates inflammation-induced insulin resistance via phospholipase C-CaMKK-AMPK signal pathway. Oxid Med Cell Longev 2021; 2021: 8542809 DOI: 10.1155/2021/8542809.
- 29 Sun P, Yin JB, Liu LH. et al. Protective role of dihydromyricetin in Alzheimer’s disease rat model associated with activating AMPK/SIRT1 signaling pathway. Biosci Rep 2019; 39 DOI: 10.1042/BSR20180902.
- 30 Shi L, Zhang T, Liang X. et al. Dihydromyricetin improves skeletal muscle insulin resistance by inducing autophagy via the AMPK signaling pathway. Mol Cell Endocrinol 2015; 409: 92-102 DOI: 10.1016/j.mce.2015.03.009.
- 31 Wu B, Lin J, Luo J. et al. Dihydromyricetin protects against diabetic cardiomyopathy in streptozotocin-induced diabetic mice. Biomed Res Int 2017; 2017: 3764370 DOI: 10.1155/2017/3764370.
- 32 Jia L, Wang Y, Sang J. et al. Dihydromyricetin inhibits alpha-synuclein aggregation, disrupts preformed fibrils, and protects neuronal cells in culture against amyloid-induced cytotoxicity. J Agric Food Chem 2019; 67: 3946-3955 DOI: 10.1021/acs.jafc.9b00922.
- 33 Wu JZ, Ardah M, Haikal C. et al. Dihydromyricetin and salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy. Transl Neurodegener 2019; 8: 18 DOI: 10.1186/s40035-019-0159-7.
- 34 Liu CM, Yang W, Ma JQ. et al. Dihydromyricetin inhibits lead-induced cognitive impairments and inflammation by the adenosine 5’-monophosphate-activated protein kinase pathway in mice. J Agric Food Chem 2018; 66: 7975-7982 DOI: 10.1021/acs.jafc.8b02433.
- 35 Saeedi P, Petersohn I, Salpea P. et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract 2019; 157: 107843 DOI: 10.1016/j.diabres.2019.107843.
- 36 Su CJ, Shen Z, Cui RX. et al. Thioredoxin-interacting protein (TXNIP) regulates parkin/PINK1-mediated mitophagy in dopaminergic neurons under high-glucose conditions: Implications for molecular links between Parkinson’s disease and diabetes. Neurosci Bull 2020; 36: 346-358 DOI: 10.1007/s12264-019-00459-5.
- 37 Chen M, Zheng H, Wei T. et al. High Glucose-induced PC12 cell death by increasing glutamate production and decreasing methyl group metabolism. Biomed Res Int 2016; 2016: 4125731 DOI: 10.1155/2016/4125731.
- 38 Sun Y, Guo C, Yuan L. et al. Cynomolgus monkeys with spontaneous type-2-diabetes-mellitus-like pathology develop alpha-synuclein alterations reminiscent of prodromal Parkinson’s disease and related diseases. Front Neurosci 2020; 14: 63 DOI: 10.3389/fnins.2020.00063.
- 39 Carvajal-Oliveros A, Dominguez-Baleon C, Zarate RV. et al. Nicotine suppresses Parkinson’s disease like phenotypes induced by synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels. Sci Rep 2021; 11: 9579 DOI: 10.1038/s41598-021-88910-4.
- 40 Feng Y, Ma J, Yuan L. beta-Methylphenylalanine exerts neuroprotective effects in a Parkinson’s disease model by protecting against tyrosine hydroxylase depletion. J Cell Mol Med 2020; 24: 9871-9880 DOI: 10.1111/jcmm.15571.
- 41 Sabry HA, Zahra MM. Icariin attenuates dopaminergic neural loss in haloperidol-induced Parkinsonism in rats via GSK-3 beta and tyrosine hydroxylase regulation mechanism. J Chem Neuroanat 2023; 136: 102385 DOI: 10.1016/j.jchemneu.2023.102385.
- 42 Zhao Y, Wu P, Wu J. et al. Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning. Eur J Nucl Med Mol Imaging 2022; 49: 2798-2811 DOI: 10.1007/s00259-022-05804-x.
- 43 Nozaki T, Sugiyama K, Asakawa T. et al. Increased anteroventral striatal dopamine transporter and motor recovery after subthalamic deep brain stimulation in Parkinson’s disease. J Neurosurg 2021; 1-11 DOI: 10.3171/2021.10.JNS211364.
- 44 Wang H, Wang L, Hu F. et al. Neuregulin-4 attenuates diabetic cardiomyopathy by regulating autophagy via the AMPK/mTOR signalling pathway. Cardiovasc Diabetol 2022; 21: 205 DOI: 10.1186/s12933-022-01643-0.
- 45 Choi SJ, Kim S, Lee WS. et al. Autophagy dysfunction in a diabetic peripheral neuropathy model. Plast Reconstr Surg 2023; 151: 355-364 DOI: 10.1097/PRS.0000000000009844.
- 46 Dong H, Yan J, Huang P. et al. miR-214-3p promotes the pathogenesis of Parkinson’s disease by inhibiting autophagy. Biomed Pharmacother 2024; 171: 116123 DOI: 10.1016/j.biopha.2024.116123.
- 47 Cheng J, Liao Y, Dong Y. et al. Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice. Autophagy 2020; 16: 2193-2205 DOI: 10.1080/15548627.2020.1719723.
- 48 Shen DF, Qi HP, Zhang WN. et al. Resveratrol promotes autophagy to improve neuronal injury in Parkinson’s disease by regulating SNHG1/miR-128-3p/SNCA Axis. Brain Sci 2023; 13 DOI: 10.3390/brainsci13081124.
- 49 Zhu J, Dou S, Jiang Y. et al. Apelin-13 protects dopaminergic neurons in MPTP-induced Parkinson’s disease model mice through inhibiting endoplasmic reticulum stress and promoting autophagy. Brain Res 2019; 1715: 203-212 DOI: 10.1016/j.brainres.2019.03.027.
- 50 Liu T, Wang P, Yin H. et al. Rapamycin reverses ferroptosis by increasing autophagy in MPTP/MPP(+)-induced models of Parkinson’s disease. Neural Regen Res 2023; 18: 2514-2519 DOI: 10.4103/1673-5374.371381.
- 51 Hua YY, Zhang Y, Gong WW. et al. Dihydromyricetin improves endothelial dysfunction in diabetic mice via oxidative stress inhibition in a SIRT3-dependent manner. Int J Mol Sci 2020; 21 DOI: 10.3390/ijms21186699.
- 52 Ling H, Zhu Z, Yang J. et al. Dihydromyricetin improves type 2 diabetes-induced cognitive impairment via suppressing oxidative stress and enhancing brain-derived neurotrophic factor-mediated neuroprotection in mice. Acta Biochim Biophys Sin (Shanghai) 2018; 50: 298-306 DOI: 10.1093/abbs/gmy003.
- 53 Guo CH, Cao T, Zheng LT. et al. Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson’s disease: Validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin. Acta Pharmacol Sin 2020; 41: 499-507 DOI: 10.1038/s41401-020-0379-5.
- 54 Ni T, Lin N, Lu W. et al. Dihydromyricetin prevents diabetic cardiomyopathy via miR-34a suppression by activating autophagy. Cardiovasc Drugs Ther 2020; 34: 291-301 DOI: 10.1007/s10557-020-06968-0.
- 55 Wang X, Hu H, Hu B. et al. Dihydromyricetin inhibits hepatitis B virus replication by activating NF-kappaB, MAPKs, and autophagy in HepG2.2.15 cells. Mol Biol Rep 2023; 50: 1403-1414 DOI: 10.1007/s11033-022-07971-4.
- 56 Liang X, Zhang T, Shi L. et al. Ampelopsin protects endothelial cells from hyperglycemia-induced oxidative damage by inducing autophagy via the AMPK signaling pathway. Biofactors 2015; 41: 463-475 DOI: 10.1002/biof.1248.
- 57 Park JS, Choe K, Lee HJ. et al. Neuroprotective effects of osmotin in Parkinson’s disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways. J Biomed Sci 2023; 30: 66 DOI: 10.1186/s12929-023-00961-z.
- 58 Wang Z, Cui J, Li D. et al. Morin exhibits a neuroprotective effect in MPTP-induced Parkinson’s disease model via TFEB/AMPK-mediated mitophagy. Phytomedicine 2023; 116: 154866 DOI: 10.1016/j.phymed.2023.154866.